{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:42:01Z","timestamp":1774053721654,"version":"3.50.1"},"reference-count":133,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T00:00:00Z","timestamp":1570406400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T00:00:00Z","timestamp":1570406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intensive Care Med"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s00134-019-05736-5","type":"journal-article","created":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T06:02:16Z","timestamp":1570428136000},"page":"1518-1539","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura"],"prefix":"10.1007","volume":"45","author":[{"name":"On behalf of the Nine-i Investigators","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8162-1508","authenticated-orcid":false,"given":"Elie","family":"Azoulay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe R.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Mariotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lene","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Knoebl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Martin-Loeches","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"P\u00e8ne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Puxty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Povoa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Barratt-Due","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Garnacho-Montero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Wendon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laveena","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Benoit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"von Bergwelt-Baildon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Maggiorini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Coppo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spero","family":"Cataland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agn\u00e8s","family":"Veyradier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andry","family":"Van de Louw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,7]]},"reference":[{"key":"5736_CR1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","volume":"325","author":"GA Rock","year":"1991","unstructured":"Rock GA, Shumak KH, Buskard NA, Canadian Apheresis Study Group et al (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 325:393\u2013397","journal-title":"N Engl J Med"},{"key":"5736_CR2","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1056\/NEJM199108083250605","volume":"325","author":"WR Bell","year":"1991","unstructured":"Bell WR, Braine HG, Ness PM, Kickler TS (1991) Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: clinical experience in 108 patients. N Engl J Med 325:398\u2013403","journal-title":"N Engl J Med"},{"key":"5736_CR3","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1182\/blood-2002-05-1401","volume":"100","author":"J Dong","year":"2002","unstructured":"Dong J, Moake JL, Nolasco L et al (2002) ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 100:4033\u20134039","journal-title":"Blood"},{"key":"5736_CR4","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood.V98.6.1765","volume":"98","author":"A Veyradier","year":"2001","unstructured":"Veyradier A, Obert B, Houllier A, Meyer D, Girma JP (2001) Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 98:1765\u20131772","journal-title":"Blood"},{"key":"5736_CR5","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/35097008","volume":"413","author":"GG Levy","year":"2001","unstructured":"Levy GG, Nichols WC, Lian EC et al (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413:488\u2013494","journal-title":"Nature"},{"key":"5736_CR6","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","volume":"339","author":"HM Tsai","year":"1998","unstructured":"Tsai HM, Lian EC (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339:1585\u20131594","journal-title":"N Engl J Med"},{"key":"5736_CR7","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","volume":"339","author":"M Furlan","year":"1998","unstructured":"Furlan M, Robles R, Galbusera M et al (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339:1578\u20131584","journal-title":"N Engl J Med"},{"key":"5736_CR8","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00134-014-3630-z","volume":"41","author":"PM Mannucci","year":"2015","unstructured":"Mannucci PM (2015) Understanding organ dysfunction in thrombotic thrombocytopenic purpura. Intensive Care Med 41:715\u2013718","journal-title":"Intensive Care Med"},{"key":"5736_CR9","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1016\/S2352-3026(16)30018-7","volume":"3","author":"E Mariotte","year":"2016","unstructured":"Mariotte E, Azoulay E, Galicier L et al (2016) Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol 3:e237\u2013e245","journal-title":"Lancet Haematol"},{"key":"5736_CR10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","volume":"158","author":"M Scully","year":"2012","unstructured":"Scully M, Hunt BJ, Benjamin S et al (2012) Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 158:323\u2013335","journal-title":"Br J Haematol"},{"key":"5736_CR11","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1538-7836.2010.03761.x","volume":"8","author":"F Peyvandi","year":"2010","unstructured":"Peyvandi F, Palla R, Lotta LA, Mackie I, Scully MA, Machin SJ (2010) ADAMTS-13 assays in thrombotic thrombocytopenic purpura. J Thromb Haemost JTH 8:631\u2013640","journal-title":"J Thromb Haemost JTH"},{"key":"5736_CR12","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","volume":"129","author":"BS Joly","year":"2017","unstructured":"Joly BS, Coppo P, Veyradier A (2017) Thrombotic thrombocytopenic purpura. Blood 129:2836\u20132846","journal-title":"Blood"},{"key":"5736_CR13","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ajh.24665","volume":"92","author":"M Grall","year":"2017","unstructured":"Grall M, Azoulay E, Galicier L et al (2017) Thrombotic thrombocytopenic purpura misdiagnosed as autoimmune cytopenia: causes of diagnostic errors and consequence on outcome. Experience of the French thrombotic microangiopathies reference centre. Am J Hematol 92:381\u2013387","journal-title":"Am J Hematol"},{"key":"5736_CR14","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1007\/s00134-012-2638-5","volume":"38","author":"V Peigne","year":"2012","unstructured":"Peigne V, Perez P, Resche Rigon M et al (2012) Causes and risk factors of death in patients with thrombotic microangiopathies. Intensive Care Med 38:1810\u20131817","journal-title":"Intensive Care Med"},{"key":"5736_CR15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00134-004-2505-0","volume":"31","author":"F Pene","year":"2005","unstructured":"Pene F, Vigneau C, Auburtin M et al (2005) Outcome of severe adult thrombotic microangiopathies in the intensive care unit. Intensive Care Med 31:71\u201378","journal-title":"Intensive Care Med"},{"key":"5736_CR16","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1097\/01.CCM.0000227659.14644.3E","volume":"34","author":"M Darmon","year":"2006","unstructured":"Darmon M, Azoulay E, Thiery G et al (2006) Time course of organ dysfunction in thrombotic microangiopathy patients receiving either plasma perfusion or plasma exchange. Crit Care Med 34:2127\u20132133","journal-title":"Crit Care Med"},{"key":"5736_CR17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","volume":"380","author":"M Scully","year":"2019","unstructured":"Scully M, Cataland SR, Peyvandi F et al (2019) Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 380:335\u2013346","journal-title":"N Engl J Med"},{"key":"5736_CR18","first-page":"8","volume":"88","author":"AM Fourmont","year":"2018","unstructured":"Fourmont AM, Zafrani L, Mariotte E et al (2018) The clinical features of cardiac involvement in patients with severe thrombotic thrombocytopenic purpura. Intensive Care Med 88:8\u201310","journal-title":"Intensive Care Med"},{"key":"5736_CR19","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.tracli.2017.05.015","volume":"24","author":"P Coppo","year":"2017","unstructured":"Coppo P (2017) French reference center for thrombotic microangiopathies. Management of thrombotic thrombocytopenic purpura. Transfus Clin Biol J Soc Francaise Transfus Sang 24:148\u2013153","journal-title":"Transfus Clin Biol J Soc Francaise Transfus Sang"},{"key":"5736_CR20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-017-2264-7","volume":"106","author":"M Matsumoto","year":"2017","unstructured":"Matsumoto M, Fujimura Y, Wada H et al (2017) Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan. Int J Hematol 106:3\u201315","journal-title":"Int J Hematol"},{"key":"5736_CR21","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/00043426-198424000-00008","volume":"6","author":"RH Sills","year":"1984","unstructured":"Sills RH (1984) Thrombotic thrombocytopenic purpura. II. Principles of therapy and guidelines for management. Am J Pediatr Hematol Oncol 6:431\u2013439","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"5736_CR22","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924\u2013926","journal-title":"BMJ"},{"key":"5736_CR23","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","volume":"328","author":"D Atkins","year":"2004","unstructured":"Atkins D, Best D, Briss PA et al (2004) Grading quality of evidence and strength of recommendations. BMJ 328:1490","journal-title":"BMJ"},{"key":"5736_CR24","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/jth.12826","volume":"13","author":"L Zafrani","year":"2015","unstructured":"Zafrani L, Mariotte E, Darmon M et al (2015) Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity. J Thromb Haemost JTH 13:380\u2013389","journal-title":"J Thromb Haemost JTH"},{"key":"5736_CR25","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1007\/s00134-013-2873-4","volume":"39","author":"E Mariotte","year":"2013","unstructured":"Mariotte E, Blet A, Galicier L et al (2013) Unresponsive thrombotic thrombocytopenic purpura in critically ill adults. Intensive Care Med 39:1272\u20131281","journal-title":"Intensive Care Med"},{"key":"5736_CR26","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s001340050289","volume":"23","author":"P Kn\u00f6bl","year":"1997","unstructured":"Kn\u00f6bl P, Rintelen C, Kornek G et al (1997) Plasma exchange for treatment of thrombotic thrombocytopenic purpura in critically ill patients. Intensive Care Med 23:44\u201350","journal-title":"Intensive Care Med"},{"key":"5736_CR27","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1007\/s001340000675","volume":"26","author":"V Gasparovi\u0107","year":"2000","unstructured":"Gasparovi\u0107 V, Radoni\u0107 R, Meji\u0107 S, Pisl Z, Radman I (2000) Possibilities and limits of treatment in patients with thrombotic thrombocytopenic purpura. Intensive Care Med 26:1690\u20131693","journal-title":"Intensive Care Med"},{"key":"5736_CR28","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/archneurol.2010.119","volume":"67","author":"TM Burrus","year":"2010","unstructured":"Burrus TM, Mandrekar J, Wijdicks EFM, Rabinstein AA (2010) Renal failure and posterior reversible encephalopathy syndrome in patients with thrombotic thrombocytopenic purpura. Arch Neurol 67:831\u2013834","journal-title":"Arch Neurol"},{"key":"5736_CR29","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1212\/WNL.0b013e3181aaea1b","volume":"73","author":"TM Burrus","year":"2009","unstructured":"Burrus TM, Wijdicks EFM, Rabinstein AA (2009) Brain lesions are most often reversible in acute thrombotic thrombocytopenic purpura. Neurology 73:66\u201370","journal-title":"Neurology"},{"key":"5736_CR30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/jth.12790","volume":"13","author":"Y Benhamou","year":"2015","unstructured":"Benhamou Y, Boelle P-Y, Baudin B et al (2015) Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center. J Thromb Haemost JTH 13:293\u2013302","journal-title":"J Thromb Haemost JTH"},{"key":"5736_CR31","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1365-2141.2008.07458.x","volume":"144","author":"V McDonald","year":"2009","unstructured":"McDonald V, Laffan M, Benjamin S, Bevan D, Machin S, Scully MA (2009) Thrombotic thrombocytopenic purpura precipitated by acute pancreatitis: a report of seven cases from a regional UK TTP registry. Br J Haematol 144:430\u2013433","journal-title":"Br J Haematol"},{"key":"5736_CR32","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.chest.2017.03.055","volume":"152","author":"E Azoulay","year":"2017","unstructured":"Azoulay E, Knoebl P, Garnacho-Montero J et al (2017) Expert statements on the standard of care in critically ill adult patients with atypical hemolytic uremic syndrome. Chest 152:424\u2013434","journal-title":"Chest"},{"key":"5736_CR33","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ajh.22091","volume":"86","author":"KK Booth","year":"2011","unstructured":"Booth KK, Terrell DR, Vesely SK, George JN (2011) Systemic infections mimicking thrombotic thrombocytopenic purpura. Am J Hematol 86:743\u2013751","journal-title":"Am J Hematol"},{"key":"5736_CR34","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.mcna.2016.09.010","volume":"101","author":"JJ Shatzel","year":"2017","unstructured":"Shatzel JJ, Taylor JA (2017) Syndromes of thrombotic microangiopathy. Med Clin North Am 101:395\u2013415","journal-title":"Med Clin North Am"},{"key":"5736_CR35","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1111\/trf.12917","volume":"54","author":"RS McClain","year":"2014","unstructured":"McClain RS, Terrell DR, Vesely SK, George JN (2014) Plasma exchange complications in patients treated for thrombotic thrombocytopenia purpura-hemolytic uremic syndrome: 2011\u20132014. Transfusion (Paris) 54:3257\u20133259","journal-title":"Transfusion (Paris)"},{"key":"5736_CR36","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/bloodadvances.2017005124","volume":"1","author":"EE Page","year":"2017","unstructured":"Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN (2017) Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Adv 1:590\u2013600","journal-title":"Blood Adv"},{"key":"5736_CR37","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00005792-196603000-00003","volume":"45","author":"E Amorosi","year":"1966","unstructured":"Amorosi E, Ultmann J (1966) Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine (Baltimore). 45:139\u2013159","journal-title":"Medicine (Baltimore)."},{"key":"5736_CR38","doi-asserted-by":"crossref","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","volume":"5","author":"P Coppo","year":"2010","unstructured":"Coppo P, Schwarzinger M, Buffet M et al (2010) Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One 5:e10208","journal-title":"PLoS One"},{"key":"5736_CR39","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1111\/j.1537-2995.2010.02653.x","volume":"50","author":"MJ Bentley","year":"2010","unstructured":"Bentley MJ, Lehman CM, Blaylock RC, Wilson AR, Rodgers GM (2010) The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange. Transfusion (Paris) 50:1654\u20131664","journal-title":"Transfusion (Paris)"},{"key":"5736_CR40","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/vox.12050","volume":"105","author":"MJ Bentley","year":"2013","unstructured":"Bentley MJ, Wilson AR, Rodgers GM (2013) Performance of a clinical prediction score for thrombotic thrombocytopenic purpura in an independent cohort. Vox Sang 105:313\u2013318","journal-title":"Vox Sang"},{"key":"5736_CR41","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","volume":"4","author":"PK Bendapudi","year":"2017","unstructured":"Bendapudi PK, Hurwitz S, Fry A et al (2017) Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol 4:e157\u2013e164","journal-title":"Lancet Haematol"},{"key":"5736_CR42","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/jth.13882","volume":"16","author":"A Li","year":"2018","unstructured":"Li A, Khalighi PR, Wu Q, Garcia DA (2018) External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment. J Thromb Haemost JTH 16:164\u2013169","journal-title":"J Thromb Haemost JTH"},{"key":"5736_CR43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jca.21257","volume":"28","author":"AA Kaplan","year":"2013","unstructured":"Kaplan AA (2013) Therapeutic plasma exchange: a technical and operational review: therapeutic plasma exchange. J Clin Apher 28:3\u201310","journal-title":"J Clin Apher"},{"key":"5736_CR44","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/bjh.12629","volume":"164","author":"HM Reeves","year":"2014","unstructured":"Reeves HM, Winters JL (2014) The mechanisms of action of plasma exchange. Br J Haematol 164:342\u2013351","journal-title":"Br J Haematol"},{"key":"5736_CR45","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/trf.12762","volume":"55","author":"N Wu","year":"2015","unstructured":"Wu N, Liu J, Yang S et al (2015) Diagnostic and prognostic values of ADAMTS13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura: diagnostic and prognostic values of ADAMTS13 during PE Therapy. Transfusion (Paris) 55:18\u201324","journal-title":"Transfusion (Paris)"},{"key":"5736_CR46","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1365-2141.2008.07276.x","volume":"142","author":"M Scully","year":"2008","unstructured":"Scully M, Yarranton H, Liesner R et al (2008) Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol 142:819\u2013826","journal-title":"Br J Haematol"},{"key":"5736_CR47","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","volume":"115","author":"JA Kremer Hovinga","year":"2010","unstructured":"Kremer Hovinga JA, Vesely SK, Terrell DR, L\u00e4mmle B, George JN (2010) Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 115:1500\u20131511","journal-title":"Blood"},{"key":"5736_CR48","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/jth.12790","volume":"13","author":"Y Benhamou","year":"2015","unstructured":"Benhamou Y, Boelle PY, Baudin B et al (2015) Cardiac troponin-i on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura: Experience of the French Thrombotic Microangiopathies Reference Center. J Thromb Haemost 13:293\u2013302","journal-title":"J Thromb Haemost"},{"key":"5736_CR49","first-page":"382","volume":"48","author":"BM Hawkins","year":"2008","unstructured":"Hawkins BM, Abu-Fadel M, Vesely SK, George JN (2008) Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review. Transfusion (Paris) 48:382\u2013392","journal-title":"Transfusion (Paris)"},{"key":"5736_CR50","doi-asserted-by":"crossref","first-page":"834","DOI":"10.5858\/2003-127-834-TTPAHU","volume":"127","author":"GA Hosler","year":"2003","unstructured":"Hosler GA, Cusumano AM, Hutchins GM (2003) Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities: a review of 56 autopsy cases. Arch Pathol Lab Med 127:834\u2013839","journal-title":"Arch Pathol Lab Med"},{"key":"5736_CR51","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/bjh.12569","volume":"163","author":"N Shah","year":"2013","unstructured":"Shah N, Rutherford C, Matevosyan K, Shen Y-M, Sarode R (2013) Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP). Br J Haematol 163:514\u2013519","journal-title":"Br J Haematol"},{"key":"5736_CR52","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2003-01-0193","volume":"102","author":"SK Vesely","year":"2003","unstructured":"Vesely SK, George JN, L\u00e4mmle B et al (2003) ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 102:60\u201368","journal-title":"Blood"},{"key":"5736_CR53","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1365-2141.2010.08385.x","volume":"151","author":"LA Lotta","year":"2010","unstructured":"Lotta LA, Mariani M, Consonni D et al (2010) Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura. Br J Haematol 151:488\u2013494","journal-title":"Br J Haematol"},{"key":"5736_CR54","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/ajh.23997","volume":"90","author":"Y Benhamou","year":"2015","unstructured":"Benhamou Y, Baudel J-L, Wynckel A et al (2015) Are platelet transfusions harmful in acquired thrombotic thrombocytopenic purpura at the acute phase? Experience of the French Thrombotic Microangiopathies Reference Center. Am J Hematol 90:127\u2013129","journal-title":"Am J Hematol"},{"key":"5736_CR55","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1111\/trf.14152","volume":"57","author":"Y Yoshii","year":"2017","unstructured":"Yoshii Y, Fujimura Y, Bennett CL, Isonishi A, Kurumatani N, Matsumoto M (2017) Implementation of a rapid assay of ADAMTS13 activity was associated with improved 30-day survival rate in patients with acquired primary thrombotic thrombocytopenic purpura who received platelet transfusions. Transfusion (Paris) 57:2045\u20132053","journal-title":"Transfusion (Paris)"},{"key":"5736_CR56","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.transci.2011.07.001","volume":"45","author":"M M\u00f6rtzell","year":"2011","unstructured":"M\u00f6rtzell M, Berlin G, Nilsson T et al (2011) Analyses of data of patients with Thrombotic Microangiopathy in the WAA registry. Transfus Apher Sci 45:125\u2013131","journal-title":"Transfus Apher Sci"},{"key":"5736_CR57","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1600-0609.2009.01331.x","volume":"83","author":"SR Cataland","year":"2009","unstructured":"Cataland SR, Yang S, Witkoff L et al (2009) Demographic and ADAMTS13 biomarker data as predictors of early recurrences of idiopathic thrombotic thrombocytopenic purpura. Eur J Haematol 83:559\u2013564","journal-title":"Eur J Haematol"},{"key":"5736_CR58","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMe1515876","volume":"374","author":"Veyradier A Von","year":"2016","unstructured":"Von Veyradier A (2016) Willebrand factor\u2013a new target for TTP treatment? N Engl J Med 374:583\u2013585","journal-title":"N Engl J Med"},{"key":"5736_CR59","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/0002-9343(87)90753-4","volume":"83","author":"M Rose","year":"1987","unstructured":"Rose M, Eldor A (1987) High incidence of relapses in thrombotic thrombocytopenic purpura. Clinical study of 38 patients. Am J Med 83:437\u2013444","journal-title":"Am J Med"},{"key":"5736_CR60","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1756-8722-1-23","volume":"1","author":"M Levandovsky","year":"2008","unstructured":"Levandovsky M, Harvey D, Lara P, Wun T (2008) Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): a 24-year clinical experience with 178 patients. J Hematol OncolJ Hematol Oncol 1:23","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"5736_CR61","doi-asserted-by":"crossref","first-page":"357","DOI":"10.7326\/0003-4819-91-3-357","volume":"91","author":"RL Ridolfi","year":"1979","unstructured":"Ridolfi RL, Hutchins GM, Bell WR (1979) The heart and cardiac conduction system in thrombotic thrombocytopenic purpura. A clinicopathologic study of 17 autopsied patients. Ann Intern Med 91:357\u2013363","journal-title":"Ann Intern Med"},{"key":"5736_CR62","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1600-0609.2008.01172.x","volume":"82","author":"DC Sane","year":"2009","unstructured":"Sane DC, Streer NP, Owen J (2009) Myocardial necrosis in patients with thrombotic thrombocytopenic purpura: pathophysiology and rationale for specific therapy. Eur J Haematol 82:83\u201392","journal-title":"Eur J Haematol"},{"key":"5736_CR63","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/jca.21510","volume":"32","author":"J Brazelton","year":"2017","unstructured":"Brazelton J, Oster RA, McCleskey B, Fuller J, Adamski J, Marques MB (2017) Increased troponin I is associated with fatal outcome in acquired thrombotic thrombocytopenic purpura. J Clin Apheresis 32:311\u2013318","journal-title":"J Clin Apheresis"},{"key":"5736_CR64","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3324\/haematol.2011.049676","volume":"97","author":"Y Benhamou","year":"2012","unstructured":"Benhamou Y, Assi\u00e9 C, Boelle PY et al (2012) Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Haematologica 97:1181\u20131186","journal-title":"Haematologica"},{"key":"5736_CR65","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s11239-016-1395-7","volume":"42","author":"G Berti-de-Marinis","year":"2016","unstructured":"Berti-de-Marinis G, Novello S, Ferrari S et al (2016) Correlation between ADAMTS13 activity and neurological impairment in acute thrombotic microangiopathy patients. J Thromb Thrombolysis 42:586\u2013592","journal-title":"J Thromb Thrombolysis"},{"key":"5736_CR66","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1111\/trf.13586","volume":"56","author":"R Goel","year":"2016","unstructured":"Goel R, King KE, Takemoto CM, Ness PM, Tobian AAR (2016) Prognostic risk-stratified score for predicting mortality in hospitalized patients with thrombotic thrombocytopenic purpura: nationally representative data from 2007 to 2012. Transfusion (Paris) 56:1451\u20131458","journal-title":"Transfusion (Paris)"},{"key":"5736_CR67","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/ajh.23455","volume":"88","author":"S Chaturvedi","year":"2013","unstructured":"Chaturvedi S, Carcioppolo D, Zhang L, Mccrae KR (2013) Management and outcomes for patients with TTP: analysis of 100 cases at a single institution. Am J Hematol 88:560\u2013565","journal-title":"Am J Hematol"},{"key":"5736_CR68","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/jth.13571","volume":"15","author":"M Scully","year":"2017","unstructured":"Scully M, Cataland S, Coppo P et al (2017) Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost JTH 15:312\u2013322","journal-title":"J Thromb Haemost JTH"},{"key":"5736_CR69","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1182\/asheducation-2015.1.637","volume":"2015","author":"P Coppo","year":"2015","unstructured":"Coppo P, Froissart A, French Reference Center for Thrombotic Microangiopathies (2015) Treatment of thrombotic thrombocytopenic purpura beyond therapeutic plasma exchange. Hematol Am Soc Hematol Educ Program 2015:637\u2013643","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"5736_CR70","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.1182\/blood-2012-02-408914","volume":"119","author":"M Moatti-Cohen","year":"2012","unstructured":"Moatti-Cohen M, Garrec C, Wolf M et al (2012) Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood 119:5888\u20135897","journal-title":"Blood"},{"key":"5736_CR71","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood-2014-02-553131","volume":"124","author":"M Scully","year":"2014","unstructured":"Scully M, Thomas M, Underwood M et al (2014) Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood 124:211\u2013219","journal-title":"Blood"},{"key":"5736_CR72","doi-asserted-by":"crossref","first-page":"e0206558","DOI":"10.1371\/journal.pone.0206558","volume":"13","author":"MG Uriol Rivera","year":"2018","unstructured":"Uriol Rivera MG, Cabello Pelegrin S, Ballester Ruiz C et al (2018) Impact of a multidisciplinary team for the management of thrombotic microangiopathy. PLoS One 13:e0206558","journal-title":"PLoS One"},{"key":"5736_CR73","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.beha.2009.07.004","volume":"22","author":"J Moake","year":"2009","unstructured":"Moake J (2009) Thrombotic thrombocytopenia purpura (TTP) and other thrombotic microangiopathies. Best Pract Res Clin Haematol 22:567\u2013576","journal-title":"Best Pract Res Clin Haematol"},{"key":"5736_CR74","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00005792-200301000-00003","volume":"82","author":"P Coppo","year":"2003","unstructured":"Coppo P, Bussel A, Charrier S et al (2003) High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura\/hemolytic-uremic syndrome. Medicine (Baltimore) 82:27\u201338","journal-title":"Medicine (Baltimore)"},{"key":"5736_CR75","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00277-009-0877-5","volume":"89","author":"CL Balduini","year":"2010","unstructured":"Balduini CL, Gugliotta L, Luppi M et al (2010) High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study. Ann Hematol 89:591\u2013596","journal-title":"Ann Hematol"},{"key":"5736_CR76","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/cei.12472","volume":"179","author":"E Becerra","year":"2015","unstructured":"Becerra E, Scully MA, Leandro MJ et al (2015) Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura. Clin Exp Immunol 179:414\u2013425","journal-title":"Clin Exp Immunol"},{"key":"5736_CR77","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/ajh.24559","volume":"91","author":"Y Benhamou","year":"2016","unstructured":"Benhamou Y, Paintaud G, Azoulay E et al (2016) Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: results of a phase II, multicenter noncomparative study. Am J Hematol 91:1246\u20131251","journal-title":"Am J Hematol"},{"key":"5736_CR78","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1182\/blood-2005-03-0848","volume":"106","author":"F Fakhouri","year":"2005","unstructured":"Fakhouri F, Vernant J-P, Veyradier A et al (2005) Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 106:1932\u20131937","journal-title":"Blood"},{"key":"5736_CR79","doi-asserted-by":"crossref","first-page":"314","DOI":"10.7326\/0003-4819-140-4-200402170-00028","volume":"140","author":"F Fakhouri","year":"2004","unstructured":"Fakhouri F, Teixeira L, Delarue R, Gr\u00fcnfeld J-P, Veyradier A (2004) Responsiveness of thrombotic thrombocytopenic purpura to rituximab and cyclophosphamide. Ann Intern Med 140:314\u2013315","journal-title":"Ann Intern Med"},{"key":"5736_CR80","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/CCM.0b013e31822e9d66","volume":"40","author":"A Froissart","year":"2012","unstructured":"Froissart A, Buffet M, Veyradier A et al (2012) Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med 40:104\u2013111","journal-title":"Crit Care Med"},{"key":"5736_CR81","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1182\/blood-2016-03-703827","volume":"127","author":"EE Page","year":"2016","unstructured":"Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN (2016) Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura. Blood 127:3092\u20133094","journal-title":"Blood"},{"key":"5736_CR82","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","volume":"118","author":"M Scully","year":"2011","unstructured":"Scully M, McDonald V, Cavenagh J et al (2011) A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 118:1746\u20131753","journal-title":"Blood"},{"key":"5736_CR83","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/jth.12114","volume":"11","author":"J-P Westwood","year":"2013","unstructured":"Westwood J-P, Webster H, McGuckin S, McDonald V, Machin SJ, Scully M (2013) Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost JTH 11:481\u2013490","journal-title":"J Thromb Haemost JTH"},{"key":"5736_CR84","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.2006.06448.x","volume":"136","author":"M Scully","year":"2007","unstructured":"Scully M, Cohen H, Cavenagh J et al (2007) Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 136:451\u2013461","journal-title":"Br J Haematol"},{"key":"5736_CR85","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/01.moh.0000170534.33517.99","volume":"12","author":"SR Cataland","year":"2005","unstructured":"Cataland SR, Wu HM (2005) Immunotherapy for thrombotic thrombocytopenic purpura. Curr Opin Hematol 12:359\u2013363","journal-title":"Curr Opin Hematol"},{"key":"5736_CR86","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2141.2006.06384.x","volume":"136","author":"SR Cataland","year":"2007","unstructured":"Cataland SR, Jin M, Ferketich AK et al (2007) An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 136:146\u2013149","journal-title":"Br J Haematol"},{"key":"5736_CR87","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2141.2007.06819.x","volume":"139","author":"SR Cataland","year":"2007","unstructured":"Cataland SR, Jin M, Lin S et al (2007) Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity. Br J Haematol 139:486\u2013493","journal-title":"Br J Haematol"},{"key":"5736_CR88","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1111\/j.1537-2995.2012.03578.x","volume":"52","author":"F Beloncle","year":"2012","unstructured":"Beloncle F, Buffet M, Coindre J-P et al (2012) Splenectomy and\/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Transfusion (Paris) 52:2436\u20132444","journal-title":"Transfusion (Paris)"},{"key":"5736_CR89","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/0140-6736(92)92869-H","volume":"340","author":"JM Durand","year":"1992","unstructured":"Durand JM, Lefevre P, Kaplanski G, Telle H, Soubeyrand J (1992) Vincristine for thrombotic thrombocytopenic purpura. Lancet Lond Engl 340:977\u2013978","journal-title":"Lancet Lond Engl"},{"key":"5736_CR90","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1182\/blood-2014-11-551580","volume":"125","author":"FA Sayani","year":"2015","unstructured":"Sayani FA, Abrams CS (2015) How I treat refractory thrombotic thrombocytopenic purpura. Blood 125:3860\u20133867","journal-title":"Blood"},{"key":"5736_CR91","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/bjh.14045","volume":"173","author":"MR Thomas","year":"2016","unstructured":"Thomas MR, Robinson S, Scully MA (2016) How we manage thrombotic microangiopathies in pregnancy. Br J Haematol 173:821\u2013830","journal-title":"Br J Haematol"},{"key":"5736_CR92","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1056\/NEJMc1213206","volume":"368","author":"J Shortt","year":"2013","unstructured":"Shortt J, Oh DH, Opat SS (2013) ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med 368:90\u201392","journal-title":"N Engl J Med"},{"key":"5736_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2018.06.002","author":"E Hern\u00e1ndez Lorente","year":"2018","unstructured":"Hern\u00e1ndez Lorente E, Lluch Garc\u00eda R, Monteagudo Santolaya E (2018) Effectiveness of bortezomib in the treatment of thrombotic thrombocytopenic purpura: Case report. Med Clin (Barc). https:\/\/doi.org\/10.1016\/j.medcli.2018.06.002","journal-title":"Med Clin (Barc)"},{"key":"5736_CR94","doi-asserted-by":"crossref","first-page":"e1277","DOI":"10.1097\/MJT.0000000000000386","volume":"23","author":"G Cabanillas","year":"2016","unstructured":"Cabanillas G, Popescu-Martinez A (2016) N-acetylcysteine for relapsing thrombotic thrombocytopenic purpura: more evidence of a promising drug. Am J Ther 23:e1277\u2013e1279","journal-title":"Am J Ther"},{"key":"5736_CR95","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1111\/jth.13716","volume":"15","author":"F Peyvandi","year":"2017","unstructured":"Peyvandi F, Scully M, Kremer Hovinga JA et al (2017) Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost JTH 15:1448\u20131452","journal-title":"J Thromb Haemost JTH"},{"key":"5736_CR96","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2018-99-112174","volume":"132","author":"P Knoebl","year":"2018","unstructured":"Knoebl P, Scully M, Cataland S et al (2018) Integrated safety results from the phase II and phase III studies with caplacizumab in patients with acquired thrombotic thrombocytopenic purpura. Blood 132:3739","journal-title":"Blood"},{"key":"5736_CR97","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1182\/blood-2018-99-112179","volume":"132","author":"SR Cataland","year":"2018","unstructured":"Cataland SR, Scully M, Peyvandi F et al (2018) Risk factors and manageability of the mainly mild mucocutaneous bleeding profile observed in aTTP patients treated with caplacizumab during the phase III hercules study. Blood 132:1142","journal-title":"Blood"},{"key":"5736_CR98","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1111\/trf.13041","volume":"55","author":"E Riviere","year":"2015","unstructured":"Riviere E, Saint-L\u00e9ger M, James C et al (2015) Platelet transfusion and catheter insertion for plasma exchange in patients with thrombotic thrombocytopenic purpura and a low platelet count. Transfusion (Paris) 55:1798\u20131802","journal-title":"Transfusion (Paris)"},{"issue":"Suppl 1","key":"5736_CR99","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/S0049-3848(02)00153-6","volume":"107","author":"P Hellstern","year":"2002","unstructured":"Hellstern P, Muntean W, Schramm W, Seifried E, Solheim BG (2002) Practical guidelines for the clinical use of plasma. Thromb Res 107(Suppl 1):S53\u2013S57","journal-title":"Thromb Res"},{"key":"5736_CR100","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.transci.2016.12.019","volume":"56","author":"P Coppo","year":"2017","unstructured":"Coppo P, French Reference Center for Thrombotic Microangiopathies (2017) Treatment of autoimmune thrombotic thrombocytopenic purpura in the more severe forms. Transfus Apher Sci 56:52\u201356","journal-title":"Transfus Apher Sci"},{"key":"5736_CR101","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1111\/j.1537-2995.2012.03646.x","volume":"52","author":"S Som","year":"2012","unstructured":"Som S, Deford CC, Kaiser ML et al (2012) Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996\u20132011. Transfusion (Paris) 52:2525\u20132532","journal-title":"Transfusion (Paris)"},{"key":"5736_CR102","first-page":"311","volume":"21","author":"A Vazquez-Mellado","year":"2016","unstructured":"Vazquez-Mellado A, Peque\u00f1o-Lu\u00e9vano M, Cantu-Rodriguez OG et al (2016) More about low-dose rituximab and plasma exchange as front-line therapy for patients with thrombotic thrombocytopenic purpura. Hematol Amst Neth 21:311\u2013316","journal-title":"Hematol Amst Neth"},{"key":"5736_CR103","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","volume":"374","author":"F Peyvandi","year":"2016","unstructured":"Peyvandi F, Scully M, Kremer Hovinga JA et al (2016) Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 374:511\u2013522","journal-title":"N Engl J Med"},{"key":"5736_CR104","first-page":"429","volume":"82","author":"E Bobbio-Pallavicini","year":"1997","unstructured":"Bobbio-Pallavicini E, Gugliotta L, Centurioni R et al (1997) Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP. Haematologica 82:429\u2013435","journal-title":"Haematologica"},{"key":"5736_CR105","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1182\/blood-2014-01-550244","volume":"124","author":"M Hie","year":"2014","unstructured":"Hie M, Gay J, Galicier L et al (2014) Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura. Blood 124:204\u2013210","journal-title":"Blood"},{"key":"5736_CR106","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2141.2005.05837.x","volume":"132","author":"P Coppo","year":"2006","unstructured":"Coppo P, Wolf M, Veyradier A et al (2006) Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol 132:66\u201374","journal-title":"Br J Haematol"},{"key":"5736_CR107","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1111\/trf.13187","volume":"55","author":"BS van der Veen","year":"2015","unstructured":"van der Veen BS, Besseling R, Hoogendoorn M (2015) Serial ADAMTS13 measurements during initial plasma exchange therapy guide decisions for management of unresponsive thrombotic thrombocytopenic purpura. Transfusion (Paris) 55:2511\u20132515","journal-title":"Transfusion (Paris)"},{"key":"5736_CR108","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/blood-2018-04-840090","volume":"132","author":"M Jestin","year":"2018","unstructured":"Jestin M, Benhamou Y, Schelpe A-S et al (2018) Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura. Blood 132:2143\u20132153","journal-title":"Blood"},{"key":"5736_CR109","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ajh.21881","volume":"86","author":"SR Cataland","year":"2011","unstructured":"Cataland SR, Scully MA, Paskavitz J et al (2011) Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura. Am J Hematol 86:87\u201389","journal-title":"Am J Hematol"},{"key":"5736_CR110","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/ejh.12706","volume":"97","author":"M Soucemarianadin","year":"2016","unstructured":"Soucemarianadin M, Benhamou Y, Delmas Y et al (2016) Twice-daily therapeutical plasma exchange-based salvage therapy in severe autoimmune thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Eur J Haematol 97:183\u2013191","journal-title":"Eur J Haematol"},{"key":"5736_CR111","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1526-0968.2004.00140.x","volume":"8","author":"E Kahwash","year":"2004","unstructured":"Kahwash E, Lockwood WB (2004) Twice daily plasma exchange in refractory thrombotic thrombocytopenic purpura. Ther Apher Dial 8:254\u2013257","journal-title":"Ther Apher Dial"},{"key":"5736_CR112","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ajh.2830380116","volume":"38","author":"JL Delgado-Lamas","year":"1991","unstructured":"Delgado-Lamas JL, Romero-Garc\u00eda F, Rodriguez-Carrillo J (1991) Treatment of thrombotic thrombocytopenic purpura using vincristine and factor VIII plasma free. Am J Hematol 38:77","journal-title":"Am J Hematol"},{"key":"5736_CR113","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-138-2-200301210-00011","volume":"138","author":"X Zheng","year":"2003","unstructured":"Zheng X, Pallera AM, Goodnough LT, Sadler JE, Blinder MA (2003) Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med 138:105\u2013108","journal-title":"Ann Intern Med"},{"key":"5736_CR114","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11239-018-1647-9","volume":"46","author":"H Al-Samkari","year":"2018","unstructured":"Al-Samkari H, Grace RF, Connors JM (2018) Ofatumumab for acute treatment and prophylaxis of a patient with multiple relapses of acquired thrombotic thrombocytopenic purpura. J Thromb Thrombolysis 46:81\u201383","journal-title":"J Thromb Thrombolysis"},{"key":"5736_CR115","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1016\/S0041-1345(02)03500-5","volume":"34","author":"M Modic","year":"2002","unstructured":"Modic M, Cernelc P, Zver S (2002) Splenectomy: the last option of immunosuppressive therapy in patients with chronic or relapsing idiopathic thrombotic thrombocytopenic purpura? Transpl Proc 34:2953\u20132954","journal-title":"Transpl Proc"},{"key":"5736_CR116","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/archsurg.136.11.1236","volume":"136","author":"J Schwartz","year":"2001","unstructured":"Schwartz J, Eldor A, Szold A (2001) Laparoscopic splenectomy in patients with refractory or relapsing thrombotic thrombocytopenic purpura. Arch Surg Chic Ill 136:1236\u20131238","journal-title":"Arch Surg Chic Ill"},{"key":"5736_CR117","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/trf.12762","volume":"55","author":"N Wu","year":"2015","unstructured":"Wu N, Liu J, Yang S et al (2015) Diagnostic and prognostic values of ADAMTS13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura: diagnostic and prognostic values of ADAMTS13 during PE therapy. Transfusion 55:18\u201324. https:\/\/doi.org\/10.1111\/trf.12762","journal-title":"Transfusion"},{"key":"5736_CR118","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1111\/j.1537-2995.2010.02653.x","volume":"50","author":"MJ Bentley","year":"2010","unstructured":"Bentley MJ, Lehman CM, Blaylock RC et al (2010) The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange. Transfusion 50:1654\u20131664. https:\/\/doi.org\/10.1111\/j.1537-2995.2010.02653.x","journal-title":"Transfusion"},{"key":"5736_CR119","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.transci.2017.06.006","volume":"56","author":"R Jajosky","year":"2017","unstructured":"Jajosky R, Floyd M, Thompson T, Shikle J (2017) Validation of the PLASMIC score at a University Medical Center. Transfus Apher Sci 56:591\u2013594. https:\/\/doi.org\/10.1016\/j.transci.2017.06.006","journal-title":"Transfus Apher Sci"},{"key":"5736_CR120","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.thromres.2018.10.010","volume":"172","author":"N Tang","year":"2018","unstructured":"Tang N, Wang X, Li D, Sun Z (2018) Validation of the PLASMIC score, a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis, in Chinese patients. Thromb Res 172:9\u201313. https:\/\/doi.org\/10.1016\/j.thromres.2018.10.010","journal-title":"Thromb Res"},{"key":"5736_CR121","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1111\/trf.14230","volume":"57","author":"CH Kim","year":"2017","unstructured":"Kim CH, Simmons SC, Williams LA et al (2017) ADAMTS13 test and\/or PLASMIC clinical score in management of acquired thrombotic thrombocytopenic purpura: a cost-effective analysis. Transfusion 57:2609\u20132618. https:\/\/doi.org\/10.1111\/trf.14230","journal-title":"Transfusion"},{"key":"5736_CR122","doi-asserted-by":"publisher","first-page":"1016.e1","DOI":"10.1016\/j.amjmed.2013.03.021","volume":"126","author":"N Balasubramaniyam","year":"2013","unstructured":"Balasubramaniyam N, Kolte D, Palaniswamy C et al (2013) Predictors of in-hospital mortality and acute myocardial infarction in thrombotic thrombocytopenic purpura. Am J Med 126:1016.e1\u20131016.e7. https:\/\/doi.org\/10.1016\/j.amjmed.2013.03.021","journal-title":"Am J Med"},{"key":"5736_CR123","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01534.x","author":"BM Hawkins","year":"2007","unstructured":"Hawkins BM, Abu-Fadel M, Vesely SK, George JN (2007) Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review. Transfusion. https:\/\/doi.org\/10.1111\/j.1537-2995.2007.01534.x","journal-title":"Transfusion"},{"key":"5736_CR124","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s00134-018-5216-7","volume":"44","author":"A-M Fourmont","year":"2018","unstructured":"Fourmont A-M, Zafrani L, Mariotte E et al (2018) The clinical features of cardiac involvement in patients with severe thrombotic thrombocytopenic purpura. Intensive Care Med 44:963\u2013965. https:\/\/doi.org\/10.1007\/s00134-018-5216-7","journal-title":"Intensive Care Med"},{"key":"5736_CR125","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1111\/trf.13586","volume":"56","author":"R Goel","year":"2016","unstructured":"Goel R, King KE, Takemoto CM et al (2016) Prognostic risk-stratified score for predicting mortality in hospitalized patients with thrombotic thrombocytopenic purpura: nationally representative data from 2007 to 2012. Transfusion 56:1451\u20131458. https:\/\/doi.org\/10.1111\/trf.13586","journal-title":"Transfusion"},{"key":"5736_CR126","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/jth.13571","volume":"15","author":"M Scully","year":"2017","unstructured":"Scully M, Cataland S, Coppo P et al (2017) Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost 15:312\u2013322. https:\/\/doi.org\/10.1111\/jth.13571","journal-title":"J Thromb Haemost"},{"key":"5736_CR127","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.ejim.2015.07.021","volume":"26","author":"A Froissart","year":"2015","unstructured":"Froissart A, Veyradier A, Hi\u00e9 M et al (2015) Rituximab in autoimmune thrombotic thrombocytopenic purpura: a success story. Eur J Intern Med 26:659\u2013665. https:\/\/doi.org\/10.1016\/j.ejim.2015.07.021","journal-title":"Eur J Intern Med"},{"key":"5736_CR128","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s11739-012-0851-4","volume":"9","author":"L Camous","year":"2014","unstructured":"Camous L, Veyradier A, Darmon M et al (2014) Macrovascular thrombosis in critically ill patients with thrombotic micro-angiopathies. Intern Emerg Med 9:267\u2013272. https:\/\/doi.org\/10.1007\/s11739-012-0851-4","journal-title":"Intern Emerg Med"},{"key":"5736_CR129","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.tracli.2017.05.015","volume":"24","author":"P Coppo","year":"2017","unstructured":"Coppo P, French Reference Center for Thrombotic Microangiopathies (2017) Management of thrombotic thrombocytopenic purpura. Transfus Clin Biol 24:148\u2013153. https:\/\/doi.org\/10.1016\/j.tracli.2017.05.015","journal-title":"Transfus Clin Biol"},{"key":"5736_CR130","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1537-2995.2007.01530.x","volume":"48","author":"L Nguyen","year":"2008","unstructured":"Nguyen L, Li X, Duvall D et al (2008) Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006. Transfusion 48:349\u2013357. https:\/\/doi.org\/10.1111\/j.1537-2995.2007.01530.x","journal-title":"Transfusion"},{"key":"5736_CR131","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1537-2995.2005.03146.x","volume":"45","author":"A Ziman","year":"2005","unstructured":"Ziman A, Mitri M, Klapper E et al (2005) Combination vincristine and plasma exchange as initial therapy in patients with thrombotic thrombocytopenic purpura: one institution\u2019s experience and review of the literature. Transfusion 45:41\u201349. https:\/\/doi.org\/10.1111\/j.1537-2995.2005.03146.x","journal-title":"Transfusion"},{"key":"5736_CR132","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1111\/j.1537-2995.2012.03578.x","volume":"52","author":"F Beloncle","year":"2012","unstructured":"Beloncle F, Buffet M, Coindre J-P et al (2012) Splenectomy and\/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Transfusion 52:2436\u20132444. https:\/\/doi.org\/10.1111\/j.1537-2995.2012.03578.x","journal-title":"Transfusion"},{"key":"5736_CR133","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1600-0609.1994.tb00649.x","volume":"52","author":"E Bobbio-Pallavicini","year":"1994","unstructured":"Bobbio-Pallavicini E, Porta C, Centurioni R et al (1994) Vincristine sulfate for the treatment of thrombotic thrombocytopenic purpura refractory to plasma-exchange. The Italian Cooperative Group for TTP. Eur J Haematol 52:222\u2013226","journal-title":"Eur J Haematol"}],"updated-by":[{"DOI":"10.1007\/s00134-019-05904-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T00:00:00Z","timestamp":1579564800000}}],"container-title":["Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-019-05736-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00134-019-05736-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-019-05736-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T03:03:31Z","timestamp":1664593411000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00134-019-05736-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,7]]},"references-count":133,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["5736"],"URL":"https:\/\/doi.org\/10.1007\/s00134-019-05736-5","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00134-019-05904-7","asserted-by":"object"}]},"ISSN":["0342-4642","1432-1238"],"issn-type":[{"value":"0342-4642","type":"print"},{"value":"1432-1238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,7]]},"assertion":[{"value":"5 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this article unfortunately contained a mistake. The penultimate row of Table\u00a04 shows INR\u2009&gt;\u20091.5 which is incorrect. The correct figure is INR\u2009&lt;\u20091.5. The authors apologize for the mistake. The correct table is given below.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2020","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this article unfortunately contained a mistake. The penultimate row of Table\ufffd\ufffd4 shows INR\ufffd\ufffd\ufffd>\ufffd\ufffd\ufffd1.5 which is incorrect. The correct figure is INR\ufffd\ufffd\ufffd<\ufffd\ufffd\ufffd1.5. The authors apologize for the mistake. The correct table is given below.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This statement is the result of independent work carried out by members of the Nine-i network of investigators. None of the authors received any honoraria or fees for this work. The Nine-i network has received research grants and sponsorships from Gilead, Fisher&Payckle, Jazz Pharma, Ablynx, Baxter, Alexion, and Astellas. Financial ties unrelated to this work are as follows. Over the last 3\u00a0years, EA received honoraria or travel expense reimbursements from Alexion, Baxter, MSD, Ablynx, Pfizer, and Gilead. IML has received honoraria or travel expense reimbursements from Biomerieux, MSD, and Gilead. AV sits on the advisory boards of Ablynx-Sanofi-Genzyme, Roche-Chugai, and Shire-Takeda. PC sits on the advisory boards of Alexion, Sanofi-Genzyme, Roche-Chugai, Octapharma, and Shire-Takeda. PP received honoraria or travel expense reimbursements from Pfizer and Orion. DB has received grants from Gilead, Astellas, Fisher-Paykel, Baxter, Alexion, and Fresenius Kabi. SC sits on the advisory boards of Alexion, Sanofi-Genzyme, and Shire-Takeda. FP and JGM have received fees from Alexion. None of the other authors has any potential conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}